Prognostic role of pre-treatment [18 f]fdg pet/ct in patients with anaplastic thyroid cancer

Hyun Jeong Kim; Hang Seok Chang; Young Hoon Ryu

doi:10.3390/cancers13164228

Prognostic role of pre-treatment [¹⁸ f]fdg pet/ct in patients with anaplastic thyroid cancer

Hyun Jeong Kim, Hang Seok Chang, Young Hoon Ryu

Department of Surgery

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Anaplastic thyroid carcinoma (ATC) is a rare but highly lethal disease. Therefore, its diagnosis at an early stage and a rapid and accurate establishment of a proper treatment strategy is warranted. Tumor glycolysis assessed by¹⁸ fluorodeoxyglucose ([¹⁸ F]FDG) positron emission tomography (PET)/computed tomography (CT) is predictive of many cancers despite its limited proven applicability to ATC. We investigated the prognostic capability of [¹⁸ F]FDG PET/CT in patients with ATC. Forty patients with ATC were subjected to [¹⁸ F]FDG PET/CT for pre-treatment evaluation. The tumor size and stage, overall survival (OS), and PET parameters, including the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were analyzed. The 1-year OS rate was 17.5% with a mean life expectancy of 7.1 months. Distant metastasis was detected solely using PET/CT in 37.5% of cases. High SUVmax, MTV, and TLG were significantly associated with poor prognosis (p < 0.001, p = 0.002, and p < 0.001, respectively). A significant difference (p < 0.001) was observed in OS between patients with a high and low tumor SUVmax. Glucose metabolism assessed by [¹⁸ F]FDG PET/CT was significantly associated with the OS of patients with ATC. PET-derived parameters such as SUVmax, MTV, and TLG are useful prognostic biomarkers for ATC.

Original language	English
Article number	4228
Journal	Cancers
Volume	13
Issue number	16
DOIs	https://doi.org/10.3390/cancers13164228
Publication status	Published - 2021 Aug 2

Bibliographical note

Funding Information:
This research was funded by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2017R1D1A1B03034388) and Yonsei University College of Medicine (6–2019–0059).

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13164228

Cite this

@article{65e03ff414654ff8b25a571f57e52eab,

title = "Prognostic role of pre-treatment [18 f]fdg pet/ct in patients with anaplastic thyroid cancer",

abstract = "Anaplastic thyroid carcinoma (ATC) is a rare but highly lethal disease. Therefore, its diagnosis at an early stage and a rapid and accurate establishment of a proper treatment strategy is warranted. Tumor glycolysis assessed by18 fluorodeoxyglucose ([18 F]FDG) positron emission tomography (PET)/computed tomography (CT) is predictive of many cancers despite its limited proven applicability to ATC. We investigated the prognostic capability of [18 F]FDG PET/CT in patients with ATC. Forty patients with ATC were subjected to [18 F]FDG PET/CT for pre-treatment evaluation. The tumor size and stage, overall survival (OS), and PET parameters, including the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were analyzed. The 1-year OS rate was 17.5% with a mean life expectancy of 7.1 months. Distant metastasis was detected solely using PET/CT in 37.5% of cases. High SUVmax, MTV, and TLG were significantly associated with poor prognosis (p < 0.001, p = 0.002, and p < 0.001, respectively). A significant difference (p < 0.001) was observed in OS between patients with a high and low tumor SUVmax. Glucose metabolism assessed by [18 F]FDG PET/CT was significantly associated with the OS of patients with ATC. PET-derived parameters such as SUVmax, MTV, and TLG are useful prognostic biomarkers for ATC.",

author = "Kim, {Hyun Jeong} and Chang, {Hang Seok} and Ryu, {Young Hoon}",

note = "Funding Information: This research was funded by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2017R1D1A1B03034388) and Yonsei University College of Medicine (6–2019–0059). Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = aug,

day = "2",

doi = "10.3390/cancers13164228",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "16",

}

TY - JOUR

T1 - Prognostic role of pre-treatment [18 f]fdg pet/ct in patients with anaplastic thyroid cancer

AU - Kim, Hyun Jeong

AU - Chang, Hang Seok

AU - Ryu, Young Hoon

N1 - Funding Information: This research was funded by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2017R1D1A1B03034388) and Yonsei University College of Medicine (6–2019–0059). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/8/2

Y1 - 2021/8/2

N2 - Anaplastic thyroid carcinoma (ATC) is a rare but highly lethal disease. Therefore, its diagnosis at an early stage and a rapid and accurate establishment of a proper treatment strategy is warranted. Tumor glycolysis assessed by18 fluorodeoxyglucose ([18 F]FDG) positron emission tomography (PET)/computed tomography (CT) is predictive of many cancers despite its limited proven applicability to ATC. We investigated the prognostic capability of [18 F]FDG PET/CT in patients with ATC. Forty patients with ATC were subjected to [18 F]FDG PET/CT for pre-treatment evaluation. The tumor size and stage, overall survival (OS), and PET parameters, including the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were analyzed. The 1-year OS rate was 17.5% with a mean life expectancy of 7.1 months. Distant metastasis was detected solely using PET/CT in 37.5% of cases. High SUVmax, MTV, and TLG were significantly associated with poor prognosis (p < 0.001, p = 0.002, and p < 0.001, respectively). A significant difference (p < 0.001) was observed in OS between patients with a high and low tumor SUVmax. Glucose metabolism assessed by [18 F]FDG PET/CT was significantly associated with the OS of patients with ATC. PET-derived parameters such as SUVmax, MTV, and TLG are useful prognostic biomarkers for ATC.

AB - Anaplastic thyroid carcinoma (ATC) is a rare but highly lethal disease. Therefore, its diagnosis at an early stage and a rapid and accurate establishment of a proper treatment strategy is warranted. Tumor glycolysis assessed by18 fluorodeoxyglucose ([18 F]FDG) positron emission tomography (PET)/computed tomography (CT) is predictive of many cancers despite its limited proven applicability to ATC. We investigated the prognostic capability of [18 F]FDG PET/CT in patients with ATC. Forty patients with ATC were subjected to [18 F]FDG PET/CT for pre-treatment evaluation. The tumor size and stage, overall survival (OS), and PET parameters, including the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were analyzed. The 1-year OS rate was 17.5% with a mean life expectancy of 7.1 months. Distant metastasis was detected solely using PET/CT in 37.5% of cases. High SUVmax, MTV, and TLG were significantly associated with poor prognosis (p < 0.001, p = 0.002, and p < 0.001, respectively). A significant difference (p < 0.001) was observed in OS between patients with a high and low tumor SUVmax. Glucose metabolism assessed by [18 F]FDG PET/CT was significantly associated with the OS of patients with ATC. PET-derived parameters such as SUVmax, MTV, and TLG are useful prognostic biomarkers for ATC.

UR - http://www.scopus.com/inward/record.url?scp=85113719530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113719530&partnerID=8YFLogxK

U2 - 10.3390/cancers13164228

DO - 10.3390/cancers13164228

M3 - Article

AN - SCOPUS:85113719530

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 16

M1 - 4228

ER -